Inhibition of the Activation and Recruitment of Microglia-Like Cells Protects Against Neomycin-Induced Ototoxicity

Molecular Neurobiology

Volumn 51, Issue 1, 2015, Pages 252-267

  Sun, Shan ^a   Yu, Huiqian ^a   Yu, Hui ^a   Honglin, Mei ^a   Ni, Wenli ^a   Zhang, Yanping ^a   Guo, Luo ^a   He, Yingzi ^a   Xue, Zhen ^a   Ni, Yusu ^a   Li, Jin ^b   Feng, Yi ^b   Chen, Yan ^a   Shao, Ruijin ^c   Chai, Renjie ^d   Li, Huawei ^a,b  

^a EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SOUTHEAST UNIVERSITY   (China)

Author keywords

CX3CL1; Hair cell death; Hearing loss; Microglia like cell

Indexed keywords

ADVERSE DRUG REACTION; CASPASE 3; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CX3CR1; CX3CR1 PROTEIN, MOUSE; DRUG ADMINISTRATION; FRACTALKINE; MINOCYCLINE; MYOSIN LIGHT CHAIN; NEOMYCIN; NEUTRALIZING ANTIBODY; PHARMACOLOGY;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN STEM RESPONSE; C57BL MOUSE; CELL ACTIVATION; CELL CULTURE; CELL LOSS; CELL SURVIVAL; CHEMICALLY INDUCED; COCHLEA; COMPLICATION; CONTROLLED STUDY; DEFICIENCY; DRUG EFFECTS; EAR DISEASE; EAR PROTECTION; ENDOTHELIUM CELL; HAIR CELL; HEARING; HEARING IMPAIRMENT; IN VITRO STUDY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; OTOTOXICITY; PATHOLOGY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMALS; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; CHEMICALLY INDUCED; CHEMOKINE CX3CL1; COCHLEA; COMPLICATIONS; DEFICIENCY; DRUG EFFECTS; EAR DISEASES; HAIR CELLS, AUDITORY; HEARING LOSS; METABOLISM; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MINOCYCLINE; MYOSIN LIGHT CHAINS; NEOMYCIN; PATHOLOGY; PHARMACOLOGY; PROTEIN BIOSYNTHESIS; RECEPTORS, CHEMOKINE; UP-REGULATION;

EID: 84964292924     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8712-y     Document Type: Article

References (79)

1. Alharazneh A, Luk L, Huth M, Monfared A, Steyger PS, Cheng AG, Ricci AJ (2011) Functional hair cell mechanotransducer channels are required for aminoglycoside ototoxicity. PLoS One 6(7):e22347. doi:10.1371/journal.pone.0022347
2. Prazma J, Postma DS, Pecorak JB, Fischer ND (1976) Ototoxicity of tobramycin sulfate. Laryngoscope 86(2):259–268. doi:10.1288/00005537-197602000-00022
3. Jiang H, Sha SH, Forge A, Schacht J (2006) Caspase-independent pathways of hair cell death induced by kanamycin in vivo. Cell Death Differ 13(1):20–30. doi:10.1038/sj.cdd.4401706
4. Strupp M, Arbusow V (2001) Acute vestibulopathy. Curr Opin Neurol 14(1):11–20. doi:10.1097/00019052-200102000-00003
5. Selimoglu E (2007) Aminoglycoside-induced ototoxicity. Curr Pharm Des 13(1):119–126. doi:10.2174/138161207779313731
6. Sha SH, Schacht J (1997) Prevention of aminoglycoside-induced hearing loss. Keio J Med 46(3):115–119. doi:10.2302/kjm.46.115
7. Yu H, Lin Q, Wang Y, He Y, Fu S, Jiang H, Yu Y, Sun S, Chen Y, Shou J, Li H (2013) Inhibition of H3K9 methyltransferases G9a/GLP prevents ototoxicity and ongoing hair cell death. Cell Death Dis 4:e506. doi:10.1038/cddis.2013.28
8. Liu K, Jiang X, Shi C, Shi L, Yang B, Xu Y, Yang W, Yang S (2013) Cochlear inner hair cell ribbon synapse is the primary target of ototoxic aminoglycoside stimuli. Mol Neurobiol 48(3):647–654. doi:10.1007/s12035-013-8454-2
9. Chen L, Xiong S, Liu Y, Shang X (2012) Effect of different gentamicin dose on the plasticity of the ribbon synapses in cochlear inner hair cells of C57BL/6J mice. Mol Neurobiol 46(2):487–494. doi:10.1007/s12035-012-8312-7
10. McCabe BF (1979) Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 88(5 Pt 1):585–589
11. McCabe BF (2004) Autoimmune sensorineural hearing loss. 1979. Ann Otol Rhinol Laryngol 113(7):526–530
12. Kanzaki J, Ouchi T (1981) Steroid-responsive bilateral sensorineural hearing loss and immune complexes. Arch Otorhinolaryngol 230(1):5–9. doi:10.1007/BF00665374
13. Hirose K, Discolo CM, Keasler JR, Ransohoff R (2005) Mononuclear phagocytes migrate into the murine cochlea after acoustic trauma. J Comp Neurol 489(2):180–194. doi:10.1002/cne.20619
14. So H, Kim H, Lee JH, Park C, Kim Y, Kim E, Kim JK, Yun KJ, Lee KM, Lee HY, Moon SK, Lim DJ, Park R (2007) Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol 8(3):338–355. doi:10.1007/s10162-007-0084-9
15. Ladrech S, Mathieu M, Puel JL, Lenoir M (2013) Supporting cells regulate the remodelling of aminoglycoside-injured organ of Corti, through the release of high mobility group box 1. Eur J Neurosci 38(6):2962–2972. doi:10.1111/ejn.12290
16. Abi-Hachem RN, Zine A, Van De Water TR (2010) The injured cochlea as a target for inflammatory processes, initiation of cell death pathways and application of related otoprotectives strategies. Recent Pat CNS Drug Discov 5(2):147–163
17. Ladrech S, Wang J, Simonneau L, Puel JL, Lenoir M (2007) Macrophage contribution to the response of the rat organ of Corti to amikacin. J Neurosci Res 85(9):1970–1979. doi:10.1002/jnr.21335
18. Bhave SA, Oesterle EC, Coltrera MD (1998) Macrophage and microglia-like cells in the avian inner ear. J Comp Neurol 398(2):241–256. doi:10.1002/(SICI)1096-9861(19980824)398:2<241::AID-CNE6>3.0.CO;2-0
19. Wang Z, Li H (2000) Microglia-like cells in rat organ of Corti following aminoglycoside ototoxicity. Neuroreport 11(7):1389–1393. doi:10.1097/00001756-200005150-00008
20. Magnus T, Schreiner B, Korn T, Jack C, Guo H, Antel J, Ifergan I, Chen L, Bischof F, Bar-Or A, Wiendl H (2005) Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosc Off J Soc Neurosc 25(10):2537–2546. doi:10.1523/JNEUROSCI.4794-04.2005
21. Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19(8):312–318. doi:10.1016/0166-2236(96)10049-7
22. Guillemin GJ, Brew BJ (2004) Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol 75(3):388–397. doi:10.1189/jlb.0303114
23. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57(1):1–9. doi:10.1016/S0169-328X(98)00040-0
24. Sinkkonen ST, Chai R, Jan TA, Hartman BH, Laske RD, Gahlen F, Sinkkonen W, Cheng AG, Oshima K, Heller S (2011) Intrinsic regenerative potential of murine cochlear supporting cells. Sci Rep 1:26. doi:10.1038/srep00026
25. Asensio VC, Campbell IL (1999) Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci 22(11):504–512. doi:10.1016/S0166-2236(99)01453-8
26. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM (1998) Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 273(37):23799–23804. doi:10.1074/jbc.273.37.23799
27. Hughes PM, Botham MS, Frentzel S, Mir A, Perry VH (2002) Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS. Glia 37(4):314–327. doi:10.1002/glia.10037
28. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385(6617):640–644. doi:10.1038/385640a0
29. Papadopoulos EJ, Sassetti C, Saeki H, Yamada N, Kawamura T, Fitzhugh DJ, Saraf MA, Schall T, Blauvelt A, Rosen SD, Hwang ST (1999) Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol 29(8):2551–2559. doi:10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO;2-T
30. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafranca MN, Adhikari S, Thompson DA, Botti P, Bacon KB, Feng L (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 95(18):10896–10901. doi:10.1073/pnas.95.18.10896
31. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276(41):37993–38001. doi:10.1074/jbc.M106434200
32. He M, Moochhala SM, Adhikari S, Bhatia M (2009) Administration of exogenous fractalkine, a CX3C chemokine, is capable of modulating inflammatory response in cecal ligation and puncture-induced sepsis. Shock 31(1):33–39. doi:10.1097/SHK.0b013e31817789da
33. Fong AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD (1998) Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 188(8):1413–1419. doi:10.1084/jem.188.8.1413
34. Haskell CA, Cleary MD, Charo IF (1999) Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 274(15):10053–10058. doi:10.1074/jbc.274.15.10053
35. Limatola C, Lauro C, Catalano M, Ciotti MT, Bertollini C, Di Angelantonio S, Ragozzino D, Eusebi F (2005) Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol 166(1–2):19–28. doi:10.1016/j.jneuroim.2005.03.023
36. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9(7):917–924. doi:10.1038/nn1715
37. Lauro C, Di Angelantonio S, Cipriani R, Sobrero F, Antonilli L, Brusadin V, Ragozzino D, Limatola C (2008) Activity of adenosine receptors type 1 Is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. J Immunol 180(11):7590–7596
38. Sato E, Shick HE, Ransohoff RM, Hirose K (2010) Expression of fractalkine receptor CX3CR1 on cochlear macrophages influences survival of hair cells following ototoxic injury. J Assoc Res Otolaryngol 11(2):223–234. doi:10.1007/s10162-009-0198-3
39. Adams B, Fitch T, Chaney S, Gerlai R (2002) Altered performance characteristics in cognitive tasks: comparison of the albino ICR and CD1 mouse strains. Behav Brain Res 133(2):351–361. doi:10.1016/S0166-4328(02)00020-7
40. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z (2003) Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 107(7):1009–1016. doi:10.1161/01.CIR.0000057548.68243.42
41. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB (1996) A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 93(24):14014–14019. doi:10.1073/pnas.93.24.14014
42. Tikka TM, Koistinaho JE (2001) Minocycline provides neuroprotection against N-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol 166(12):7527–7533
43. Raghavendra V, Tanga F, DeLeo JA (2003) Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 306(2):624–630. doi:10.1124/jpet.103.052407
44. Corbacella E, Lanzoni I, Ding D, Previati M, Salvi R (2004) Minocycline attenuates gentamicin induced hair cell loss in neonatal cochlear cultures. Hear Res 197(1–2):11–18. doi:10.1016/j.heares.2004.03.012
45. Sohmer H, Feinmesser M (1967) Cochlear action potentials recorded from the external ear in man. Ann Otol Rhinol Laryngol 76(2):427–435
46. Wang J, Menchenton T, Yin S, Yu Z, Bance M, Morris DP, Moore CS, Korneluk RG, Robertson GS (2010) Over-expression of X-linked inhibitor of apoptosis protein slows presbycusis in C57BL/6J mice. Neurobiol Aging 31(7):1238–1249. doi:10.1016/j.neurobiolaging.2008.07.016
47. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262
48. Eshraghi AA, Wang J, Adil E, He J, Zine A, Bublik M, Bonny C, Puel JL, Balkany TJ, Van De Water TR (2007) Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicity. Hear Res 226(1–2):168–177. doi:10.1016/j.heares.2006.09.008
49. Dean RA, Overall CM (2007) Proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics MCP 6(4):611–623. doi:10.1074/mcp.M600341-MCP200
50. Owolabi SA, Saab CY (2006) Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn. FEBS Lett 580(18):4306–4310. doi:10.1016/j.febslet.2006.06.087
51. Shan S, Hong-Min T, Yi F, Jun-Peng G, Yue F, Yan-Hong T, Yun-Ke Y, Wen-Wei L, Xiang-Yu W, Jun M, Guo-Hua W, Ya-Ling H, Hua-Wei L, Ding-Fang C (2011) New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson’s disease. Neurobiol Aging 32(3):443–458. doi:10.1016/j.neurobiolaging.2009.03.004
52. Sun S, Cao H, Han M, Li TT, Pan HL, Zhao ZQ, Zhang YQ (2007) New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis. Pain 129(1–2):64–75. doi:10.1016/j.pain.2006.09.035
53. Rizzi MD, Hirose K (2007) Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 15(5):352–357. doi:10.1097/MOO.0b013e3282ef772d
54. Hirose K, Sato E (2011) Comparative analysis of combination kanamycin-furosemide versus kanamycin alone in the mouse cochlea. Hear Res 272(1–2):108–116. doi:10.1016/j.heares.2010.10.011
55. Huth ME, Ricci AJ, Cheng AG (2011) Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol 2011:937861. doi:10.1155/2011/937861
56. Behrbohm H, Kaschke O, Nawka T, Swift A (2009) Ear, nose, and throat diseases: with head and neck surgery. In: Stammberger H (ed)3rd edn. Thieme Medical Publishers, Stuttgart, New York, p 14–16
57. Ehret G (1978) Stiffness gradient along the basilar membrane as a basis for spatial frequency analysis within the cochlea. J Acoust So Am 64(6):1723–1726. doi:10.1121/1.382153
58. Sha SH, Taylor R, Forge A, Schacht J (2001) Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res 155(1–2):1–8. doi:10.1016/S0378-5955(01)00224-6
59. Fu R, Shen Q, Xu P, Luo JJ, Tang Y (2014) Phagocytosis of microglia in the central nervous system diseases. Mol Neurobiol. doi:10.1007/s12035-013-8620-6
60. Lue LF, Kuo YM, Beach T, Walker DG (2010) Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol Neurobiol 41(2–3):115–128. doi:10.1007/s12035-010-8106-8
61. Fujioka M, Kanzaki S, Okano HJ, Masuda M, Ogawa K, Okano H (2006) Proinflammatory cytokines expression in noise-induced damaged cochlea. J Neurosci Res 83(4):575–583. doi:10.1002/jnr.20764
62. Miller RJ, Jung H, Bhangoo SK, White FA (2009) Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol 194:417–449. doi:10.1007/978-3-540-79090-7_12
63. Chapman GA, Moores K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ (2000) Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosc Off J Soc Neurosci 20(15):RC87
64. Chapman GA, Moores KE, Gohil J, Berkhout TA, Patel L, Green P, Macphee CH, Stewart BR (2000) The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol 392(3):189–195. doi:10.1016/S0014-2999(00)00117-5
65. Lindia JA, McGowan E, Jochnowitz N, Abbadie C (2005) Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain Off J Am Pain Soc 6(7):434–438. doi:10.1016/j.jpain.2005.02.001
66. Re DB, Przedborski S (2006) Fractalkine: moving from chemotaxis to neuroprotection. Nat Neurosci 9(7):859–861. doi:10.1038/nn0706-859
67. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91(4):521–530. doi:10.1016/S0092-8674(00)80438-9
68. Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC (2004) Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci 20(5):1150–1160. doi:10.1111/j.1460-9568.2004.03593.x
69. Zhang M, Xu G, Liu W, Ni Y, Zhou W (2012) Role of fractalkine/CX3CR1 interaction in light-induced photoreceptor degeneration through regulating retinal microglial activation and migration. PLoS One 7(4):e35446. doi:10.1371/journal.pone.0035446
70. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR (2007) Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun 21(5):642–651. doi:10.1016/j.bbi.2006.11.003
71. Erichsen D, Lopez AL, Peng H, Niemann D, Williams C, Bauer M, Morgello S, Cotter RL, Ryan LA, Ghorpade A, Gendelman HE, Zheng J (2003) Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol 138(1–2):144–155. doi:10.1016/S0165-5728(03)00117-6
72. Clark AK, Malcangio M (2012) Microglial signalling mechanisms: cathepsin S and fractalkine. Exp Neurol 234(2):283–292. doi:10.1016/j.expneurol.2011.09.012
73. Ransohoff RM, Liu L, Cardona AE (2007) Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol 82:187–204. doi:10.1016/S0074-7742(07)82010-1
74. Streit WJ, Davis CN, Harrison JK (2005) Role of fractalkine (CX3CL1) in regulating neuron-microglia interactions: development of viral-based CX3CR1 antagonists. Curr Alzheimer Res 2(2):187–189. doi:10.2174/1567205053585765
75. Cipriani R, Villa P, Chece G, Lauro C, Paladini A, Micotti E, Perego C, De Simoni MG, Fredholm BB, Eusebi F, Limatola C (2011) CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci Off J Soc Neurosci 31(45):16327–16335. doi:10.1523/JNEUROSCI.3611-11.2011
76. Leonardi-Essmann F, Emig M, Kitamura Y, Spanagel R, Gebicke-Haerter PJ (2005) Fractalkine-upregulated milk-fat globule EGF factor-8 protein in cultured rat microglia. J Neuroimmunol 160(1–2):92–101. doi:10.1016/j.jneuroim.2004.11.012
77. Schulte A, Schulz B, Andrzejewski MG, Hundhausen C, Mletzko S, Achilles J, Reiss K, Paliga K, Weber C, John SR, Ludwig A (2007) Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. Biochem Biophys Res Commun 358(1):233–240. doi:10.1016/j.bbrc.2007.04.100
78. Zhu W, Acosta C, MacNeil B, Cortes C, Intrater H, Gong Y, Namaka M (2013) Elevated expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the dorsal root ganglia and spinal cord in experimental autoimmune encephalomyelitis: implications in multiple sclerosis-induced neuropathic pain. BioMed Res Int 2013:14. doi:10.1155/2013/480702
79. Wolf Y, Yona S, Kim KW, Jung S (2013) Microglia, seen from the CX3CR1 angle. Front Cell Neurosci 7:26. doi:10.3389/fncel.2013.00026